April 2024: The TGA approved an alternative to the XYLOCAINE 2% with Epinephrine 1:200,000 20ml ampoule product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until September 30, 2024. Contact Us for more details.

​

April 2024: The TGA approved an alternative to the 25 micrograms/24 hours estradiol transdermal patches product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until October 31, 2024. Contact Us for more details.

​

April 2024: NELARABINE-REACH is now approved in Australia and is available at all wholesalers. Contact Us for more details.

​

December 2023: The TGA approved an alternative to the XYLOCAINE 2% with Epinephrine 1:200,000 20ml ampoule product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until April 30, 2024. Contact Us for more details.

​

December 2023: The TGA approved an alternative to the amidotrizoate meglumine, sodium amidotrizoate oral solution product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until April 30, 2024. Contact Us for more details.

​

December 2023: ROMIDEPSIN-REACH 10 mg for injection is now available at all wholesalers. Contact Us for more details.

​

December 2023: NELARABINE-REACH 250 mg/50 mL for injection is now available under S19A of the Therapeutic Goods Act, 1989 until April 30, 2024. Contact Us for more details.

 

November 2023: The TGA approved an alternative to the 25 micrograms/24 hours estradiol transdermal patches product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until March 31, 2024. Contact Us for more details.

​​

October 2023: Dexrazoxane is granted Orphan Drug Designation by the TGA in Australia.  Contact Us for more details.

​

October 2023: Reach Pharmaceuticals launches CARBOPROST-REACH solution for injection in Australia. The product is the first carboprost formulation launched since the innovator brand was discontinued in 2013. Contact Us for more details.

​​

June 2023: Cefuroxime 125mg/5 mL granules for oral suspension is now listed on the PBS. Contact Us for more details.

​​

September 2023: The TGA approved the supply of NELARABINE-REACH solution for injection through early access to a medicine under evaluation for inclusion on the ARTG in Australia. Contact Us for more details.

​​

August 2023: The TGA approved an alternative to the 25 micrograms/24 hours estradiol transdermal patches product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until September 30, 2023. Contact Us for more details.

​​

August 2023: The TGA approved an alternative to the 50 micrograms/24 hours estradiol transdermal patches product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until September 30, 2023. Contact Us for more details.

​

July 2023: The TGA approved CYCLOPHOSPHAMIDE-REACH powder for injection. Contact Us for more details.

​​

July 2023: The TGA approved two alternatives to the glucagon 1mg powder and solvent for solution for injection product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until October 31, 2023. Contact Us for more details.

​​

July 2023: The TGA approved alternatives to the doxepin hydrochloride 25 mg and 50mg capsules products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until November 30, 2023 and 30 September 2023 respectively. Contact Us for more details.

​​

June 2023: The TGA approved CARBOPROST-REACH solution for injection. Contact Us for more details.

​

June 2023: The TGA approved the importation of an alternative to cefuroxime 125mg/5 mL granules for oral suspension under S19A of the Therapeutic Goods Act, 1989 until June 30, 2024. Contact Us for more details.

​​

May 2023: The TGA approved the importation of an alternative to the sugar free 40 mg trimethoprim and 200 mg sulfamethoxazole oral liquid in shortage under S19A of the Therapeutic Goods Act, 1989 until August 31, 2023. Contact Us for more details.

​​

April 2023: The TGA approved the importation of an alternative to captopril 25 mg/5 mL oral solution under S19A of the Therapeutic Goods Act, 1989 until April 30, 2024. Contact Us for more details.

​

April 2023: The TGA approved the importation of an alternative to prochlorperazine mesilate 12.5mg/1mL injection ampoule under S19A of the Therapeutic Goods Act, 1989 until November 30, 2023. Contact Us for more details.

​​

March 2023: The TGA approved the importation of DISTACLOR cefaclor 250 mg/5 mL granules for oral suspension (UK) under S19A of the Therapeutic Goods Act, 1989 until November 30, 2023.

​​

January 2023: The TGA approved the importation of KEFORAL cefalexin 250 mg/5 mL granules for oral suspension under S19A of the Therapeutic Goods Act, 1989 until December 31, 2023.

​​

December 2022: REACH received Orphan Drug Designation for Nelarabine for infusion from the TGA in Australia.

​​

December 2022: REACH received approval for ROMIDEPSIN-REACH powder for injection in Australia.

​

December 2022: The TGA approved the importation of AMOXICILLIN 125MG/5ML ORAL SUSPENSION SUGAR FREE BP (ATHLONE) under S19A of the Therapeutic Goods Act, 1989 until June 30, 2023.

​​

November 2022: The TGA approved the importation of METRONIDAZOLE 200MG/5ML ORAL SUSPENSION (ROSEMONT) under S19A of the Therapeutic Goods Act, 1989 until February 28, 2023.

​​

August 2022: The TGA approved the importation of OLENA fluoxetine hydrochloride 20 mg dispersible tablet under S19A of the Therapeutic Goods Act, 1989 until November 30, 2022.

​​

August 2022: The TGA approved the importation of AMOXICILLIN 250MG/5ML ORAL SUSPENSION SUGAR FREE BP (KENT) under S19A of the Therapeutic Goods Act, 1989 until February 28, 2023.

​​

​July 2022: Reach received Orphan Drug Designation for Carboprost for injection from the Therapeutic Goods Administration.

​

June 2022: Our online store is now live! Visit the Shop tab to order the available products or click here.

​​

​June 2022: Reach is pleased to announce the approval of THIOTEPA-REACH 15 mg powder for injection and THIOTEPA-REACH 100 mg powder for injection in Australia.  For more details please contact us on sales@reach-pharma.com. The PI is available from the TGA website, click here 

​​

​June 2022: Reach is pleased to announce the launch of Cipla Isoprenaline for injection 0.2mg/mL, 25 ampoules and Cipla Isoprenaline for injection 1mg/5mL, 10 ampoules.  For more details please contact us on sales@reach-pharma.com. The PI is available from the TGA website, click here 

​

June 2022: Reach is pleased to announce the launch of Metabolics Potassium Citrate 1.08g modified release tablets.  For more details please contact us on sales@reach-pharma.com. The CMI is available here

​​

January 2022: The TGA approved the importation of Xylanaest 1% with Epinephrine 1:200,000 5ml ampoule under S19A of the Therapeutic Goods Act, 1989 until November 30, 2022. 

​​

December 2021: The TGA approved the importation of Thiotepa for Injection, USP 15 mg AND Thiotepa for injection Injection, USP 100 mg under S19A of the Therapeutic Goods Act, 1989 until September 30, 2022. 

​​

October 2020: Icatibant 30mg/3mL is available from Reach for supply to hospitals in Australia. The product was listed on the PBS in October.​​ The PI is available from the TGA website, click here

​​

June 2020: The TGA approved the importation of Isoproterenol Hydrochloride Injection, USP 1 mg/5 mL solution for injection ampoule under S19A of the Therapeutic Goods Act, 1989 until April 30, 2022.